Is Vident International Equity Strategy ETF (VIDI) a Strong ETF Right Now?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 13 2024
0mins
Source: NASDAQ.COM
Overview of Vident International Equity Strategy ETF (VIDI): Launched in 2013, VIDI is a smart beta ETF that aims to outperform the World ETFs segment by utilizing a principles-based selection strategy and balancing risk across developed and emerging markets, with an expense ratio of 0.61% and a 12-month dividend yield of 3.50%.
Comparison with Other ETFs: While VIDI has shown positive performance, investors may also consider lower-cost traditional market cap weighted ETFs like Vanguard Total International Stock ETF (VXUS) and Vanguard FTSE Developed Markets ETF (VEA), which have significantly lower expense ratios and larger asset bases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JAZZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JAZZ
Wall Street analysts forecast JAZZ stock price to fall
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 236.170
Low
188.00
Averages
218.92
High
263.00
Current: 236.170
Low
188.00
Averages
218.92
High
263.00
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jazz Pharmaceuticals' LAGOON Trial Results Fail to Meet Primary Endpoint
- Trial Overview: Jazz Pharmaceuticals' LAGOON trial did not meet its primary endpoint of overall survival, as Zepzelca's efficacy, whether used alone or in combination with irinotecan, did not outperform the control group, highlighting limitations in treating relapsed small cell lung cancer.
- Safety Analysis: Despite failing to meet the primary endpoint, Zepzelca's safety profile remained consistent with known characteristics, with treatment-related adverse events occurring at rates of 78.5% for monotherapy and 95% for combination therapy, indicating relative safety in clinical applications.
- Market Impact: The announcement of the LAGOON trial results may negatively affect Jazz Pharmaceuticals' stock price, particularly as the company's 2026 guidance remains unaffected, leading investors to adopt a cautious outlook on future market performance.
- Next Steps: Jazz Pharmaceuticals has shared the trial results with the FDA and plans to discuss post-marketing requirements for Zepzelca's second-line indication, demonstrating the company's proactive approach in seeking regulatory support despite challenges.
See More
Jazz Pharmaceuticals' LAGOON Trial Results Fail to Meet Expectations
- Trial Overview: Jazz Pharmaceuticals' LAGOON trial evaluated Zepzelca in patients with relapsed small cell lung cancer, revealing that neither monotherapy nor combination with irinotecan met the primary overall survival endpoint, indicating limited efficacy in this indication.
- Study Design and Participants: The trial was a randomized, open-label Phase 3 study enrolling patients with extensive-stage SCLC who progressed after first-line platinum-based chemotherapy, with median overall survival being similar across treatment arms, highlighting the challenges in improving outcomes for relapsed SCLC.
- Safety Profile: The safety data for Zepzelca remained consistent with prior studies, with no new safety signals observed, indicating that its safety profile is still reliable despite the lack of expected efficacy.
- Next Steps: Jazz has shared the LAGOON results with the FDA and plans to discuss post-marketing requirements for Zepzelca's second-line indication, although the outcome does not affect its existing approval for first-line maintenance treatment or the company's 2026 financial guidance.
See More
Jazz Pharmaceuticals' Zepzelca Fails Phase 3 Trial Endpoint
- Trial Results: Jazz Pharmaceuticals plc announced that its Phase 3 LAGOON trial for Zepzelca (lurbinectedin) in relapsed metastatic small cell lung cancer did not meet its primary endpoint, with a median overall survival of 8.7 months for the monotherapy group and 10.9 months for the combination therapy, both failing to show significant improvement over the control group's 10.7 months.
- Safety Profile Consistency: Although the trial did not achieve its primary efficacy endpoint, Zepzelca's safety profile remained consistent with previous clinical studies, indicating potential market viability in terms of safety.
- FDA Follow-Up Discussions: The company has shared these results with the FDA and plans to discuss next steps regarding post-marketing requirements for Zepzelca's second-line indication, reflecting the company's strategic focus on regulatory compliance and future market positioning.
- Financial Guidance Unaffected: Jazz Pharmaceuticals assured that the trial data will not impact its 2026 guidance, demonstrating confidence in future performance despite a 1.77% decline in pre-market trading on Nasdaq.
See More
Jazz Pharmaceuticals' Lung Cancer Therapy Trial Fails
- Trial Outcome Disappointment: Jazz Pharmaceuticals announced that its lung cancer therapy Zepzelca failed to meet the primary endpoint of overall survival in the Phase 3 LAGOON trial, leading to a premarket stock decline and raising concerns about the therapy's efficacy.
- No New Safety Issues: Despite the trial's failure, the company reported no new safety concerns, with the drug arms demonstrating a tolerability profile consistent with established safety, providing some confidence for future treatment options.
- FDA Accelerated Approval: Zepzelca is already available in the U.S. under the FDA’s accelerated approval as a second-line therapy for metastatic small cell lung cancer, which constitutes about 13% of all lung cancer cases, with continued approval contingent on positive results from confirmatory trials.
- Future Plans Discussion: Jazz Pharmaceuticals has shared the trial data with the FDA and plans to discuss post-marketing conditions for this indication in a future meeting, indicating the company's commitment to addressing the situation and exploring future treatment pathways.
See More
Jazz Pharmaceuticals Announces LAGOON Trial Results for Zepzelca
- Trial Results Underperform: Jazz Pharmaceuticals' LAGOON trial failed to meet its primary endpoint, as Zepzelca monotherapy or in combination with irinotecan did not significantly improve overall survival compared to the control group, indicating limitations in its second-line treatment efficacy and potentially affecting market acceptance.
- Safety Profile Remains Stable: Despite the disappointing results, Zepzelca's safety profile was consistent with known characteristics, with no new safety signals identified, suggesting manageable risks in clinical applications that may help maintain confidence among physicians and patients.
- Contrast with IMforte Trial: The LAGOON results starkly contrast with the IMforte trial, which received approval in 2025 and demonstrated significant survival improvements when Zepzelca was combined with atezolizumab in first-line maintenance therapy, highlighting efficacy differences across treatment stages.
- Future Regulatory Discussions: Jazz Pharmaceuticals has shared the LAGOON results with the FDA and plans to discuss next steps; while the trial results do not impact the 2026 financial guidance, they may pose regulatory challenges for Zepzelca's second-line indication.
See More
Jazz Pharmaceuticals Presents 21 Abstracts at SLEEP 2026 Conference
- Research Commitment: Jazz Pharmaceuticals will present 21 abstracts, including 11 late-breaking ones, at the SLEEP 2026 conference from June 14-17, 2026, showcasing the company's ongoing dedication to advancing treatments for narcolepsy and idiopathic hypersomnia through new clinical research and real-world evidence.
- Patient Focus: The research emphasizes the daily realities faced by narcolepsy patients, highlighting the importance of studies that reflect real-world experiences to inform treatment decisions, thereby enhancing patient quality of life, particularly in terms of reducing long-term sodium intake.
- Clinical Data: At SLEEP 2026, Jazz will present findings from multiple studies, including the impact of low-sodium oxybate treatment on narcolepsy patients, demonstrating correlations between improved nighttime sleep quality and reduced daytime sleepiness, potentially offering more effective treatment options for patients.
- Market Positioning: Jazz's Xywav® is the only FDA-approved low-sodium oxybate specifically for treating narcolepsy and idiopathic hypersomnia, recognized for its significant cardiovascular safety, which is expected to further solidify its leadership position in the rare sleep disorder treatment market.
See More
Jazz Pharmaceuticals' LAGOON Trial Results Fail to Meet Primary Endpoint
- Trial Overview: Jazz Pharmaceuticals' LAGOON trial did not meet its primary endpoint of overall survival, as Zepzelca's efficacy, whether used alone or in combination with irinotecan, did not outperform the control group, highlighting limitations in treating relapsed small cell lung cancer.
- Safety Analysis: Despite failing to meet the primary endpoint, Zepzelca's safety profile remained consistent with known characteristics, with treatment-related adverse events occurring at rates of 78.5% for monotherapy and 95% for combination therapy, indicating relative safety in clinical applications.
- Market Impact: The announcement of the LAGOON trial results may negatively affect Jazz Pharmaceuticals' stock price, particularly as the company's 2026 guidance remains unaffected, leading investors to adopt a cautious outlook on future market performance.
- Next Steps: Jazz Pharmaceuticals has shared the trial results with the FDA and plans to discuss post-marketing requirements for Zepzelca's second-line indication, demonstrating the company's proactive approach in seeking regulatory support despite challenges.
See More
Jazz Pharmaceuticals' LAGOON Trial Results Fail to Meet Expectations
- Trial Overview: Jazz Pharmaceuticals' LAGOON trial evaluated Zepzelca in patients with relapsed small cell lung cancer, revealing that neither monotherapy nor combination with irinotecan met the primary overall survival endpoint, indicating limited efficacy in this indication.
- Study Design and Participants: The trial was a randomized, open-label Phase 3 study enrolling patients with extensive-stage SCLC who progressed after first-line platinum-based chemotherapy, with median overall survival being similar across treatment arms, highlighting the challenges in improving outcomes for relapsed SCLC.
- Safety Profile: The safety data for Zepzelca remained consistent with prior studies, with no new safety signals observed, indicating that its safety profile is still reliable despite the lack of expected efficacy.
- Next Steps: Jazz has shared the LAGOON results with the FDA and plans to discuss post-marketing requirements for Zepzelca's second-line indication, although the outcome does not affect its existing approval for first-line maintenance treatment or the company's 2026 financial guidance.
See More
Jazz Pharmaceuticals' Zepzelca Fails Phase 3 Trial Endpoint
- Trial Results: Jazz Pharmaceuticals plc announced that its Phase 3 LAGOON trial for Zepzelca (lurbinectedin) in relapsed metastatic small cell lung cancer did not meet its primary endpoint, with a median overall survival of 8.7 months for the monotherapy group and 10.9 months for the combination therapy, both failing to show significant improvement over the control group's 10.7 months.
- Safety Profile Consistency: Although the trial did not achieve its primary efficacy endpoint, Zepzelca's safety profile remained consistent with previous clinical studies, indicating potential market viability in terms of safety.
- FDA Follow-Up Discussions: The company has shared these results with the FDA and plans to discuss next steps regarding post-marketing requirements for Zepzelca's second-line indication, reflecting the company's strategic focus on regulatory compliance and future market positioning.
- Financial Guidance Unaffected: Jazz Pharmaceuticals assured that the trial data will not impact its 2026 guidance, demonstrating confidence in future performance despite a 1.77% decline in pre-market trading on Nasdaq.
See More
Jazz Pharmaceuticals' Lung Cancer Therapy Trial Fails
- Trial Outcome Disappointment: Jazz Pharmaceuticals announced that its lung cancer therapy Zepzelca failed to meet the primary endpoint of overall survival in the Phase 3 LAGOON trial, leading to a premarket stock decline and raising concerns about the therapy's efficacy.
- No New Safety Issues: Despite the trial's failure, the company reported no new safety concerns, with the drug arms demonstrating a tolerability profile consistent with established safety, providing some confidence for future treatment options.
- FDA Accelerated Approval: Zepzelca is already available in the U.S. under the FDA’s accelerated approval as a second-line therapy for metastatic small cell lung cancer, which constitutes about 13% of all lung cancer cases, with continued approval contingent on positive results from confirmatory trials.
- Future Plans Discussion: Jazz Pharmaceuticals has shared the trial data with the FDA and plans to discuss post-marketing conditions for this indication in a future meeting, indicating the company's commitment to addressing the situation and exploring future treatment pathways.
See More
Jazz Pharmaceuticals Announces LAGOON Trial Results for Zepzelca
- Trial Results Underperform: Jazz Pharmaceuticals' LAGOON trial failed to meet its primary endpoint, as Zepzelca monotherapy or in combination with irinotecan did not significantly improve overall survival compared to the control group, indicating limitations in its second-line treatment efficacy and potentially affecting market acceptance.
- Safety Profile Remains Stable: Despite the disappointing results, Zepzelca's safety profile was consistent with known characteristics, with no new safety signals identified, suggesting manageable risks in clinical applications that may help maintain confidence among physicians and patients.
- Contrast with IMforte Trial: The LAGOON results starkly contrast with the IMforte trial, which received approval in 2025 and demonstrated significant survival improvements when Zepzelca was combined with atezolizumab in first-line maintenance therapy, highlighting efficacy differences across treatment stages.
- Future Regulatory Discussions: Jazz Pharmaceuticals has shared the LAGOON results with the FDA and plans to discuss next steps; while the trial results do not impact the 2026 financial guidance, they may pose regulatory challenges for Zepzelca's second-line indication.
See More
Jazz Pharmaceuticals Presents 21 Abstracts at SLEEP 2026 Conference
- Research Commitment: Jazz Pharmaceuticals will present 21 abstracts, including 11 late-breaking ones, at the SLEEP 2026 conference from June 14-17, 2026, showcasing the company's ongoing dedication to advancing treatments for narcolepsy and idiopathic hypersomnia through new clinical research and real-world evidence.
- Patient Focus: The research emphasizes the daily realities faced by narcolepsy patients, highlighting the importance of studies that reflect real-world experiences to inform treatment decisions, thereby enhancing patient quality of life, particularly in terms of reducing long-term sodium intake.
- Clinical Data: At SLEEP 2026, Jazz will present findings from multiple studies, including the impact of low-sodium oxybate treatment on narcolepsy patients, demonstrating correlations between improved nighttime sleep quality and reduced daytime sleepiness, potentially offering more effective treatment options for patients.
- Market Positioning: Jazz's Xywav® is the only FDA-approved low-sodium oxybate specifically for treating narcolepsy and idiopathic hypersomnia, recognized for its significant cardiovascular safety, which is expected to further solidify its leadership position in the rare sleep disorder treatment market.
See More
